Charles River Laboratories International Inc (NYSE:CRL) Institutional Investors Sentiment Change

August 26, 2018 - By Andrea Pope

Charles River Laboratories International, Inc. (NYSE:CRL) Logo

Sentiment for Charles River Laboratories International Inc (NYSE:CRL)

Charles River Laboratories International Inc (NYSE:CRL) institutional sentiment increased to 1.13 in 2018 Q1. Its up 0.05, from 1.08 in 2017Q4. The ratio increased, as 140 investment professionals increased or opened new equity positions, while 124 cut down and sold positions in Charles River Laboratories International Inc. The investment professionals in our partner’s database reported: 44.28 million shares, down from 44.57 million shares in 2017Q4. Also, the number of investment professionals holding Charles River Laboratories International Inc in their top 10 equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 31 Reduced: 93 Increased: 96 New Position: 44.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $5.84 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 46.04 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

The stock decreased 0.37% or $0.45 during the last trading session, reaching $121.51. About 439,177 shares traded or 29.12% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 12.87% since August 26, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Analysts await Charles River Laboratories International, Inc. (NYSE:CRL) to report earnings on November, 8. They expect $1.39 earnings per share, up 6.92 % or $0.09 from last year’s $1.3 per share. CRL’s profit will be $66.76 million for 21.85 P/E if the $1.39 EPS becomes a reality. After $1.62 actual earnings per share reported by Charles River Laboratories International, Inc. for the previous quarter, Wall Street now forecasts -14.20 % negative EPS growth.

Channing Capital Management Llc holds 2.62% of its portfolio in Charles River Laboratories International, Inc. for 701,583 shares. Van Berkom & Associates Inc. owns 613,141 shares or 1.99% of their US portfolio. Moreover, Copper Rock Capital Partners Llc has 1.93% invested in the company for 301,980 shares. The Illinois-based Ariel Investments Llc has invested 1.66% in the stock. Norris Perne & French Llp Mi, a Michigan-based fund reported 99,543 shares.

Since January 1, 0001, it had 0 insider buys, and 16 sales for $13.15 million activity.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Ratings analysis reveals 50% of Charles River’s analysts are positive. Out of 10 Wall Street analysts rating Charles River, 5 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $102 while the high is $145. The stock’s average target of $119.13 is -1.96% below today’s ($121.51) share price. CRL was included in 11 notes of analysts from March 14, 2018. The firm has “Hold” rating given on Friday, April 20 by MUFG Securities Americas Inc. The company was maintained on Thursday, August 9 by Jefferies. Bank of America maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Monday, July 16 with “Buy” rating. The stock has “Buy” rating by Jefferies on Tuesday, April 24. The company was maintained on Tuesday, August 21 by Credit Suisse. The rating was upgraded by RBC Capital Markets on Tuesday, July 17 to “Outperform”. Morgan Stanley maintained it with “Equal-Weight” rating and $102 target in Wednesday, March 14 report. KeyBanc Capital Markets upgraded the shares of CRL in report on Friday, June 15 to “Overweight” rating. Raymond James upgraded the stock to “Outperform” rating in Thursday, August 23 report. On Thursday, August 9 the stock rating was maintained by Barclays Capital with “Equal-Weight”.

More notable recent Charles River Laboratories International, Inc. (NYSE:CRL) news were published by: Benzinga.com which released: “Earnings Scheduled For August 8, 2018” on August 08, 2018, also Seekingalpha.com with their article: “Regeneron’s Pain Is Novartis’ Gain” published on August 14, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on August 23, 2018. More interesting news about Charles River Laboratories International, Inc. (NYSE:CRL) were released by: Benzinga.com and their article: “10 Biggest Price Target Changes For Tuesday” published on August 21, 2018 as well as Seekingalpha.com‘s news article titled: “Charles River Labs: The Growth Is Real” with publication date: August 09, 2018.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.